By Greg Harrison

From their appearance in the documentary Died Suddenly to detailed scientific analysis five years later, the unusual white fibrous structures reported by embalmers are now receiving systematic study.

Two recently published, peer-reviewed papers examine these observations from different angles—one through a multi-year international survey of embalmers and the other through molecular analysis of extracted material.

Published in the International Journal of Innovative Research in Medical Science (IJIRMS), the papers combine large-scale observational data with Raman spectroscopy to investigate what they describe as an emerging systemic vascular pathology involving amyloid-like protein aggregates.

The first study, Self-Reported Observations of Unusual White Fibrous Structures in Embalmed Corpses: Multi-Year Survey Results from Embalmers in Five Countries, 2022–2025, documents the reported frequency and characteristics of these structures across the United States, Canada, the United Kingdom, Australia, and New Zealand:

ijirms.in/index.php/ijirms/article/view/2201

The second study, Raman Spectroscopic Characterization of Anomalous Intravascular Fibrous Casts: Evidence for Stage-Dependent β-Sheet-Enriched Protein Maturation, examines their molecular composition and proposes that the structures may develop through a progressive protein-maturation process:

ijirms.in/index.php/ijirms/article/view/2202

Together, these papers represent a critical milestone in documenting, characterizing, and explaining a pervasive, systemic vascular pathology that has emerged globally since 2021. By bringing together large-scale epidemiological data and high-resolution molecular spectroscopy, they collectively identify a novel, potentially catastrophic disease process involving the formation of systemic, amyloid-like protein aggregates within the human vasculature.

The significance of these findings cannot be overstated. They provide the necessary scientific bridge between the anecdotal reports of frontline deathcare professionals and the rigorous requirements of forensic pathology, characterizing these “white fibrous structures” not as standard blood clots, but as a new form of post-mortem—and likely ante-mortem—amyloidosis.

This summary details the epidemiological scope, the molecular proof, and the grave implications for global public health.

The Epidemiological Evidence

The first study, Self-Reported Observations of Unusual White Fibrous Structures in Embalmed Corpses, provides the necessary statistical foundation for this investigation. For years, the medical establishment dismissed reports from embalmers as anecdotal, misidentified post-mortem clotting, or the result of embalming fluid interactions.

This study systematically dismantled that dismissal through a four-year, international, cross-sectional survey of over 800 embalmers across five countries.

The Emerging Pattern

The core finding is the clear, temporal correlation between the observation of these structures and the post-2020 era. Respondents reported that these rubbery, fibrous, white masses were almost entirely absent from their practice prior to 2020. The first reports began to surface in 2020 and accelerated dramatically in 2021.

This timeline is a critical marker that demands immediate investigation into the environmental or therapeutic interventions introduced concurrently.

The consistency of these reports across five different nations suggests a common, systemic cause rather than localized procedural variation.

Prevalence and Scope

Perhaps more alarming than the timing is the prevalence. Embalmers reported seeing these structures in 19% to 27% of the corpses they prepared. In forensic and thanatological terms, a 20%+ prevalence of a previously unseen, obstructive vascular pathology is not a medical curiosity; it is a population-level medical emergency.

These structures are not merely “clots”; they are described as tough, elastic, and rubbery, often filling the entire vascular lumen and necessitating specialized techniques to bypass.

By documenting this as a consistent, multi-year, and international phenomenon, the study establishes a “safety signal” that is impossible to ignore. It suggests that these structures are the macroscopic endpoint of a pathology that is likely affecting a significant portion of the living population as well.

The Molecular Proof

While the first paper documents the “what,” the second paper, Raman Spectroscopic Characterization of Anomalous Intravascular Fibrous Casts, provides the “how” and the “why.” Using Raman microspectroscopy—a technique that probes the molecular architecture of proteins by analyzing the vibrational modes of the peptide backbone—this study definitively distinguishes these “white fibrous structures” from conventional post-mortem thrombi, or clots.

The Structural Signature

Raman spectroscopy revealed that these structures are characterized by an advanced state of β-sheet enrichment. In protein chemistry, the transition from a native-like, α-helical state—typical of soluble fibrinogen—to a β-sheet-rich configuration is the molecular hallmark of amyloidogenesis.

The study confirms that these structures are not “clots” in the traditional sense, but are instead atypical protein aggregates.

The researchers identified a “spectroscopic maturation pattern” in which the protein backbone progresses from a native-like state toward a highly ordered, aggregation-advanced β-sheet configuration.

This structural transition explains why these masses are so mechanically resilient, rubbery, and resistant to the body’s natural clot-dissolving mechanisms, known as fibrinolysis. They are fundamentally built to be permanent.

Compositional Anomaly

The Kjeldahl and ion-exchange chromatography analyses further confirm this non-canonical nature. The amino acid profile—marked by elevated proline and lysine with extremely low cysteine—differs fundamentally from human fibrinogen.

This compositional signature points toward an exogenous or highly altered protein source that is not consistent with standard blood-coagulation biology.

The lack of cysteine, in particular, is significant, as most native blood proteins rely on disulfide bonds for stability; these aggregates, however, are stabilized by the sheer force of their β-sheet-rich architecture.

Synthesizing the Findings

When we integrate the findings of these two papers with the forensic evidence provided by investigators like Tom Haviland, a coherent and devastating picture emerges: we are witnessing a systemic, spike-protein-templated amyloidosis.

Protein Misfolding as a “Prion-Like” Cascade

The data suggest that the “white fibrous structures” are the result of a templated misfolding reaction. The key pieces of the puzzle are as follows:

Proteolytic Activation: The spike protein, when circulating systemically, is proteolytically cleaved by host enzymes, such as neutrophil elastase, which was identified in the compositional analysis.

The Seed: This cleavage releases specific peptide sequences—the “WALTZ sequences”—that contain high-probability amyloidogenic motifs. These sequences act as “seeds,” or templates, for protein misfolding.

Templated Recruitment: These seeds possess a high affinity for fibrinogen. When they encounter soluble fibrinogen in the blood, they induce a conformational change, forcing the fibrinogen to misfold into a rigid, β-sheet-rich amyloid fibril.

Self-Propagation: This is the “prionic” element. Once the amyloid scaffold is initiated, it acts as a permanent, reactive surface that continuously “scavenges” and converts the remaining soluble fibrinogen in the blood. This explains why the structures appear to branch, grow, and “gel” even post-removal—they are self-propagating, thermodynamics-driven reactors.

The Clinical and Diagnostic Crisis

The existence of this pathology is serious for three primary reasons that threaten the integrity of modern clinical practice.

1. Resistance to Standard Physiology

Normal blood clots are dynamic, temporary structures designed to be broken down by the body’s fibrinolytic system. These “white fibrous structures” are effectively the opposite: they are structurally matured amyloid fibrils that are inherently resistant to proteolysis.

They are built to be permanent. Their presence in the vasculature creates obstructive masses that the body cannot naturally clear, leading to chronic, systemic vascular compromise that can persist for years, potentially decades.

2. Systemic, Not Localized

These are not isolated events. The 20% prevalence rate reported by embalmers indicates a systemic exposure.

This suggests that the “seed” for this amyloidosis is circulating widely within the population, and the “white clots” are simply the macroscopic manifestation of a process occurring at the microscopic level throughout the entire circulatory system.

This implies that many patients currently suffering from unexplained cardiovascular issues, “long-term” inflammation, or peripheral vascular resistance may be harboring these microscopic amyloid seeds.

3. The Failure of Diagnostic Detection

Perhaps the most concerning aspect is the failure of the medical establishment to even detect this pathology. Because these structures are fundamentally different from standard clots, they often go undetected or are misdiagnosed.

Standard clinical assays for clotting, such as D-dimer tests or coagulation panels, are designed for fibrin-based thrombi. They are often incapable of detecting these amyloid-like aggregates, meaning patients may suffer from systemic obstruction and vascular inflammation while appearing “normal” on standard diagnostic tests. This diagnostic blind spot allows the pathology to progress unchecked until it reaches a critical, life-threatening mass.

The Forensic Imperative

The data presented in these two papers, when taken together, constitute a forensic identification of a new, systemic protein-misfolding disease.

The epidemiological survey, Article #1, provides the scope and temporal onset, while the structural analysis, Article #2, identifies the pathological hallmark—a systemic, spike-protein-templated amyloidosis. We are no longer dealing with a fringe hypothesis; we are dealing with documented, reproducible, and widespread spectroscopic evidence of a fundamental structural remodeling of human blood proteins.

This situation requires an immediate and transparent response from the global medical and research communities. Priority must be given to:

• Ultrastructural characterization of these aggregates via X-ray fibre diffraction and transmission electron microscopy to confirm the cross-β architecture.
• Proteomic identification of the constituent proteins to confirm the role of the spike-protein motifs.
• Development of diagnostic protocols capable of detecting amyloidogenic protein misfolding in the living patient.

The “white fibrous structures” encountered by embalmers are the macroscopic “canary in the coal mine.” They are the definitive evidence of a systemic pathology that alters the very architecture of the blood.

Continuing to ignore this evidence—or categorizing it as a post-mortem artifact—is not just scientifically unsound; it is a failure of medical responsibility in the face of an emerging and pervasive systemic health crisis.

The evidence is now in the public record; the only remaining question is how long it will take for the institutions tasked with protecting public health to confront this new, unprecedented biological reality.